Renalytix (LON:RENX) Trading Down 26.4% – What’s Next?

Renalytix Plc (LON:RENX) shares dropped 26.4% during mid-day trading on Wednesday . The company traded as low as GBX 3.74 and last traded at GBX 4.12. Approximately 2,113,685 shares changed hands during mid-day trading, an increase of 374% from the average daily volume of 445,819 shares. The stock had previously closed at GBX 5.60.

Renalytix Trading Down 21.6%

The company has a quick ratio of 2.42, a current ratio of 0.24 and a debt-to-equity ratio of -72.91. The business’s fifty day moving average is GBX 6.03 and its 200 day moving average is GBX 6.95. The stock has a market cap of £19.19 million, a PE ratio of -0.63 and a beta of 2.10.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).